BioLight Life Sciences Ltd. (BOLT.TA)

BioLight Life Sciences Ltd. (BOLT.TA) — VMCI valuation read

BioLight Life Sciences Ltd. (BOLT.TA) carries a VMCI composite of 38/100, 13 points below the Healthcare sector median of 50. Among mid-cap names, that gap places BOLT.TA in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The BOLT.TA insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads BOLT.TA trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.2x leaves covenant headroom, the line to track on BioLight Life Sciences Ltd.'s next 10-Q.

BOLT.TA held flat 0.0% over the trailing 7 days, with a +0.2% read on a 30-day basis.